New diabetes drug shows promise in 12-Week trial
NCT ID NCT00998881
First seen Jan 04, 2026 · Last updated Jun 12, 2026 · Updated 17 times
Summary
This study tested a new diabetes medicine called MP-513 (Teneligliptin) in 203 Japanese adults with type 2 diabetes. The goal was to see if the drug safely lowers blood sugar levels over 12 weeks. Participants took either the drug or a placebo pill, and researchers measured changes in HbA1c (a long-term blood sugar marker) and fasting glucose. This is a disease-control study, not a cure, as diabetes requires ongoing management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Sapporo, Hokkaido, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.